IP Library › Granted Patent US 9,540,659
Granted Patent B2
US 9,540,659 · App. 14/410,983 · Granted Jan 10, 2017

Modified adeno-associated virus vector compositions

Inventors: Beverly L. Davidson (Iowa City, IA); Maria Scheel (Iowa City, IA); Ryan Boudreau (Iowa City, IA); Alejandro Mas Monteys (Iowa City, IA)
Assignee: University of Iowa Research Foundation
C12N15/86C12N2750/14141C12N2750/14143C12N2830/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,540,659
App. No.
14/410,983
Granted
Jan 10, 2017
Kind
B2
Abstract

An adeno-associated virus filler component comprising a nucleic acid of between 3300 and 4200 nucleotides in length is disclosed.

Claims (18)

1. An adeno-associated virus (AAV) filler component comprising a nucleic acid having at least 90% identity to SEQ ID NO:1 or SEQ ID NO:2, wherein the nucleic acid is between 3500 and 4000 nucleotides.

2. An adeno-associated virus (AAV) filler component consisting of a nucleic acid having at least 90% identity to SEQ ID NO:1 or SEQ ID NO:2.

3. The AAV filler component of claim 2 , wherein the nucleic acid is between 3500 and 4000 nucleotides.

4. The AAV filler component of claim 1 , wherein the nucleic acid is between 3700 and 3850 nucleotides.

5. A recombinant adeno-associated virus (AAV) vector comprising the filler component of claim 1 operably linked to an expression cassette, wherein the AAV vector is approximately 5 kb in length.

6. The AAV vector of claim 5 , wherein the expression cassette comprises a promoter.

7. The AAV vector of claim 6 , wherein the promoter is a pol III promoter.

8. The AAV vector of claim 7 , wherein the promoter is a mU6 promoter.

9. The AAV vector of claim 5 , further comprising a target sequence.

10. The AAV vector of claim 9 , wherein the target sequence is an RNAi molecule.

11. The AAV vector of claim 5 , wherein the AAV vector is an AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, or AAV8 serotype.

12. The AAV vector of claim 5 , further comprising an inverted terminal repeat (ITR) of any one of serotype AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, or AAV8.

13. The AAV filler component of claim 1 , wherein the nucleic acid has at least 95% identity to SEQ ID NO:1 or SEQ ID NO:2.

14. The AAV filler component of claim 1 , wherein the nucleic acid has at least 98% identity to SEQ ID NO:1 or SEQ ID NO:2.

15. The AAV filler component of claim 1 , wherein the nucleic acid has at least 99% identity to SEQ ID NO:1 or SEQ ID NO:2.

16. The AAV filler component of claim 2 , wherein the nucleic acid has at least 95% identity to SEQ ID NO:1 or SEQ ID NO:2.

17. The AAV filler component of claim 2 , wherein the nucleic acid has at least 98% identity to SEQ ID NO:1 or SEQ ID NO:2.

18. The AAV filler component of claim 2 , wherein the nucleic acid has at least 99% identity to SEQ ID NO:1 or SEQ ID NO:2.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 1, 2016
From: MAS MONTEYS, ALEJANDRO
To: UNIVERSITY OF IOWA RESEARCH FOUNDATION
Reel/Frame 040190/0783 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 25, 2015
From: DAVIDSON, BEVERLY L.; SCHEEL, MARIA; BOUDREAU, RYAN
To: UNIVERSITY OF IOWA RESEARCH FOUNDATION
Reel/Frame 035251/0978 →
Continuity (2)
Provisional Application 61668839 · Jul 6, 2012
Related Publication 20150184197A1 · Jul 2, 2015